From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer - Scorecard - MDSpire

From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

  • By

  • Dianne Bosch

  • Kim J. M. van der Velden

  • Aart Beeker

  • Hendrik P. van den Berg

  • André M. Bergman

  • Maarten J. van der Doelen

  • Alfons J. M. van den Eertwegh

  • Mathijs P. Hendriks

  • Thomas M. A. Kerkhofs

  • Addy C. M. van de Luijtgaarden

  • Niven Mehra

  • Reindert J. A. van Moorselaar

  • Metin Tascilar

  • Walter L. Vervenne

  • Nir I. Weijl

  • Carin A. Uyl-de Groot

  • Peter F. A. Mulders

  • Malou C. P. Kuppen

  • Inge M. van Oort

  • May 9, 2026

  • 0 min

Share

Clinical Scorecard: Utilization and Outcomes of Olaparib in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Insights from Real-World Genomic Testing Practices

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingReal-world clinical practice in the Netherlands, with potential implications for broader settings.

Key Highlights

  • Olaparib showed more favorable outcomes when initiated earlier in taxane-naïve patients, emphasizing the importance of timing in treatment.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Monitor overall survival (OS), progression-free survival (PFS), and PSA response post-olaparib initiation, as per EAU guidelines.

      Risks

        Patient & Prescribing Data

        Olaparib was administered to 27 out of 35 eligible BRCAm patients, based on specific eligibility criteria.

        Clinical Best Practices

        • Implement routine genomic testing for mCRPC patients to identify those who may benefit from olaparib.

        Related Resources & Content

        Original Source(s)

        From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

        • by Dianne Bosch, Kim J. M. van der Velden, Aart Beeker, Hendrik P. van den Berg, André M. Bergman, Maarten J. van der Doelen, Alfons J. M. van den Eertwegh, Mathijs P. Hendriks, Thomas M. A. Kerkhofs, Addy C. M. van de Luijtgaarden, Niven Mehra, Reindert J. A. van Moorselaar, Metin Tascilar, Walter L. Vervenne, Nir I. Weijl, Carin A. Uyl-de Groot, Peter F. A. Mulders, Malou C. P. Kuppen, Inge M. van Oort

        • May 9, 2026

        Related Content

        Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity

        Differentiation of hepatocellular carcinoma from hepatic hemangioma using diffusion-derived vessel density map-based radiomics features

        Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study